Metabolic Disorders and their Transformative Impact on Female Reproductive Health

Fahmida Channa[1,*]

[1]Sindh College Education, Sindh, Pakistan
*Corresponding author: fahmidachanna1056@gmail.com

Abstract

Female reproductive health is significantly influenced by metabolic disorders such as polycystic ovary syndrome (PCOS), metabolic syndrome, obesity, type 2 diabetes mellitus (T2DM), and thyroid disorder. This chapter examines the prevalence and risk factors for these conditions and their pathophysiology, emphasizing their interrelationship and the classic manifestations in women. Key mechanisms such as insulin resistance, hyperandrogenism, adipocyte dysfunction, inflammation, and hormonal imbalances, with their roles in menstrual irregularities, infertility, ovulatory dysfunction, pregnancy complications, earlier menopause, and gynecological disorders, are discussed. The chapter also reviews diagnostic and clinical approaches with emphasis on the fact that an individualized approach based on lifestyle modifications, pharmacotherapy, and hormonal treatment is necessary. The need for preventive measures, educational initiatives, early detection, and targeted interventions to combat the growing cost of metabolic disorders among women, is highlighted. The chapter concludes by finding main research gaps and recommending future directions to enhance understanding of underlying mechanisms, improve interventions, and improve reproductive outcomes for women affected by metabolic disorders.

Keywords: Metabolic disorders, Female reproductive health, Hormonal imbalances, Infertility, Pregnancy complications.

Cite this Article as: Channa F, 2025. Metabolic disorders and their transformative impact on female reproductive health. In: Kausar R, Nisa ZU, Jamil M and Bashir I (eds), Integrated Health and Sustainability: Plants, Wildlife, and Genetic Resilience. Unique Scientific Publishers, Faisalabad, Pakistan, pp: 135-143. https://doi.org/10.47278/book.HH/2025.72

A Publication of Unique Scientific Publishers

Chapter No: 25-019

Received: 21-Feb-2025
Revised: 08-March-2025
Accepted: 12-May-2025

Introduction

Metabolic disorders include a number of complications that impair biochemical processes of the body, such as the absorption of nutrients, and energy production. These disorders are classified depending on the metabolic process including lipid, carbohydrate, amino acid and nucleic acid metabolism (Chiang et al., 2014). There are different types of classifications with their own different pathways and associated diseases like diabetes mellitus in carbohydrate metabolism and familial hypercholesterolemia in lipid metabolism (American Diabetes Association, 2020). Metabolic disorders including diabetes, obesity, and PCOS have a huge impact on female reproductive health. Such conditions predispose to menstrual irregularities, impaired fertility, and pregnancy complications (Balen et al., 2016a). For example, insulin resistance associated with PCOS increases the chances of gestational diabetes and other pregnancy complications (Cassar et al., 2016).

1 Background and Epidemiology

Metabolic disorders significantly arise in women due to physiological factors such as hormonal imbalances during the reproductive period, pregnancy, and menopause.

1.1 Prevalence of Metabolic Disorders in Women

This is a global public health problem as metabolic disorders are common among women of reproductive age. For example, PCOS is found in 5-20% of women worldwide and may be higher among certain people (Azziz et al., 2016). Incidence of obesity is similarly prevalent in almost 15% of women globally and rates are higher in lower and middle-income countries owing to urbanization, sedentary lifestyles, and dietary changes (WHO, 2021). To design effective public health approaches, and these trends underscore the rationale for considering the prevalence and consequences of metabolic disorders in women. Targeted interventions are needed to decrease the primary risk factors (diet and physical activity) associated with metabolic disorders in women (Legro et al., 2013).

1.2 Risk Factors

The genetic, environmental, and lifestyle factors combine to produce metabolic disorders in women. For example, FTO and IRS1 are variants for obesity and diabetes; CYP17 and CYP11A are linked with hormonal imbalances in PCOS (Rosenfield, 2015; Loos & Yeo, 2022). Exposure to endocrine-disrupting chemicals such as those contained in plastics can increase the risks of obesity and insulin resistance (Heindel et al., 2015). Furthermore, poor diet, physical inactivity, and chronic stress impose tremendous detrimental effects on metabolic health (Flegal et al., 2016).

2 Major Metabolic Disorders Affecting Women

Disorders such as PCOS, metabolic syndrome, obesity, T2DM, and thyroid dysfunction mainly affect women's reproductive health (Figure 1).

2.1 PCOS

It is a complex metabolic disorder prevalent among women of reproductive age. It involves hyperandrogenism, chronic anovulation, and polycystic–ovarian morphology. It is the leading cause of female infertility (Fauser et al., 2012a). It also increases the risk of metabolic syndrome, obesity, and cardiovascular disease, which can have far more consequences on female reproductive health (Balen et al., 2016b).

2.1.1 Pathophysiology of PCOS

Its pathogenesis is based on hormonal, metabolic, and genetic interactions that affect the hypothalamic-pituitary-ovarian (HPO) axis and metabolic homeostasis.

2.1.1.1 Hormonal Imbalance

Hyperandrogenism results from increased androgen secretion by the ovarian theca cells in response to high levels of luteinizing hormone (LH). The hypothalamus increases LH levels due to increased gonadotropin-releasing hormone (GnRH) pulse frequency (Escobar-Morreale, 2018).

2.1.1.2 Insulin Resistance

Hyperinsulinemia causes direct hyperandrogenism, as it stimulates theca cells in the ovary and suppresses the synthesis of sex hormone binding globulin (SHBG) in the liver, raising free androgen levels. Insulin resistance also damages ovarian steroidogenesis and follicular development and causes ovulatory dysfunction (Dumesic et al., 2015).

2.1.1.3 Chronic Inflammation

PCOS is often associated with chronic inflammation. Chronic inflammation enhances insulin resistance and hyperandrogenism which further exacerbates inflammation. It forms a vicious circle that disrupts ovarian function (Aboeldalyl et al., 2021).

2.1.1.4 Genetic and Environmental Factors

Genetic studies have revealed various genes associated with steroidogenesis and insulin signaling. Variations in these genes can disrupt hormonal regulation and metabolic processes thus increasing susceptibility to PCOS. Environmental factors such as endocrine-disrupting chemicals and lifestyle and dietary habits also increase the chances of PCOS (Chang et al., 2024).

2.2 Metabolic Syndrome

A combination of interrelated conditions i.e. abdominal obesity, insulin resistance, hypertension, and dyslipidemia is referred to as a metabolic syndrome. It is a serious risk to female reproductive health. It may also cause conditions such as PCOS, infertility, and pregnancy complications (Fauser et al., 2012b). The influence of metabolic syndrome on women's reproductive health is predominantly due to its impact on the hormonal balance and insulin resistance that is associated with ovulatory dysfunction (Zehravi et al., 2021).

2.2.1 Pathophysiology of Metabolic Syndrome

Its pathogenesis mainly involves insulin resistance and endothelial dysfunction, therefore, it increases the risk of cardiovascular disease and T2DM.

2.2.1.1 Insulin Resistance

The pathophysiology of metabolic syndrome is mediated by insulin resistance and impairs glucose homeostasis. Hyperinsulinemia can result from insulin resistance and it worsens glucose levels as well as contributes to the development of T2DM (Nolan & Prentki, 2019).

2.2.1.2 Endothelial Dysfunction

Endothelial dysfunction is mediated through insulin resistance and associated metabolic disturbances. The blood vessels become less able to dilate. Endothelial dysfunction can further cause atherosclerosis and cardiovascular disease (Sowers et al., 2001).

2.3 Obesity

Obesity is a significant metabolic disorder with major adverse impacts on reproductive health by many mechanisms ranging from disruption of the hormonal axis to chronic inflammation. Elevated levels of leptin and insulin resistance predispose obese women to irregular menstrual cycles, anovulation, and infertility (Brewer & Balen, 2010). Other reproductive conditions such as PCOS, can also be potentially worsened by obesity, as obesity promotes increased androgen levels and worsens insulin resistance, affecting ovarian function (Pasquali et al., 2007). Obesity can also lead to complications such as gestational diabetes and preeclampsia (Catalano & Shankar, 2017).

2.3.1 Pathophysiology of Obesity

Obesity is a chronic condition and its pathogenesis is based on behavioral, genetic, and physiological factors.

2.3.1.1 Hormonal Imbalance

An imbalance in hormones such as leptin, insulin, ghrelin, estrogen, growth hormone, and thyroid hormone can lead to obesity. Their altered levels in the body prevent weight loss by affecting metabolism, appetite, and body fat distribution (Rethink Obesity, 2023).

2.3.1.2 Energy Imbalance

Fat accumulation occurs when there is an energy imbalance between consumed and expended calories. Diet along with social, economic, and environmental factors can cause such imbalance (Yoo, 2018). Studies have shown that people who consumed fast food were found to weigh 6kg more than those with less fast food intake. Lack of physical activity and a sedentary lifestyle also lead to obesity (Duffey et al., 2007).

2.3.1.3 Genetic Factors

Genetic studies have found over 400 genes associated with T2DM (Srinivasan et al., 2021). Mutation in genes like fat mass and obesity-associated (FTO), melanocortin-4-receptor (MC4R), and leptin receptor can lead to obesity. Genetic causes of obesity can be monogenic (mutation in a single gene), polygenic (mutation in many genes), or syndromic (neurodevelopmental abnormalities). The presence of altered genes can cause increased appetite, increased calorie intake, reduced satiety, and increased sedentary behavior (Thaker 2017; Martins et al., 2018).

2.3.1.4 Adipocyte Dysfunction

In obesity, adipocytes (fat cells) become hypertrophic and dysfunctional and produce an imbalance in adipokine secretion. Ultimately, a state of proinflammation and insulin resistance arises that contributes to the advancement of metabolic diseases, such as diabetes (Gregor & Hotamisligil, 2011; Blüher, 2019).

2.3.1.5 Inflammation

Obesity-induced inflammation is due to the infiltration of immune cells (macrophages) into adipose tissue. This inflammatory response can impair insulin signaling and increase insulin resistance and metabolic dysfunction (Kim & Lee, 2021).

2.3.1.6 Lipotoxicity

It occurs when excess fat accumulates in tissues other than adipose i.e. liver and muscle. It impairs the normal functioning of cells and causes insulin resistance. It can lead to the development of metabolic disorders like Type 2 Diabetes (Samuel & Shulman, 2012).

2.4 T2DM

T2DM is a growing epidemic in women of reproductive age and is associated with several reproductive health complications. Women with T2DM, insulin resistance and hyperglycemia often have menstrual irregularities and are at an increased risk for anovulation (BRICKMAN et al., 2018). Additionally, T2DM causes adverse pregnancy outcomes including gestational diabetes, preeclampsia, and fetal growth restriction (American Diabetes Association, 2021). Diabetic women have elevated blood glucose that can damage the placenta leading to miscarriage and congenital anomalies (Göbl et al., 2011).

2.4.1Pathophysiology of T2DM

It is a chronic metabolic disorder and occurs due to insulin resistance, beta cell dysfunction, and increased glucose production.

2.4.1.1 Insulin Resistance

Insulin resistance is the hallmark feature of type 2 diabetes. Consequently, it impairs glucose uptake in muscle, liver, and adipose tissues leading to elevated blood glucose levels (Weyer et al., 1999; DeFronzo, 2004).

2.4.1.2 Beta Cell Dysfunction

With time, the pancreas tries to regulate insulin levels by making more insulin. However, due to constant metabolic stress beta cells begin to fail, causing an insulin deficiency and hyperglycemia (Taylor et al., 2018).

2.4.1.3 Hyperglycemia

Chronic hyperglycemia is the consequence of the combination of insulin resistance and beta cell dysfunction. It can cause problems such as cardiovascular disease, kidney failure, and neuropathy (Ohiagu et al., 2021).

2.5 Thyroid Disorders

Hypothyroidism and hyperthyroidism have a great impact on female reproductive health. They adversely affect menstrual function, ovulation, hormonal balance, and outcomes of pregnancy (Poppe, 2003). With hypothyroidism, menstrual irregularities, reduced fertility, and increased risk of miscarriage are common (Krassas et al., 2010). Hyperthyroidism is less common but may cause menstrual disturbances and pregnancy complications, such as preeclampsia and fetal growth restriction (Alexander et al., 2017). Pregnant women with thyroid dysfunction can have significant impacts on the neurological development of the child (Lazarus et al., 2012).

2.5.1Pathophysiology of Thyroid Disorders

These disorders most often result from abnormalities of the hypothalamic-pituitary-thyroid (HPT) axis, defects of the thyroid gland, or autoimmune processes. The main causes of these disorders are hyperthyroidism and hypothyroidism, with other significant conditions described below:

2.5.1.1 Hyperthyroidism

It is overproduction of the thyroid hormone and it raises the metabolic rate. Common causes of hyperthyroidism are:

Graves' disease: The Thyroid gland is stimulated by thyrotropin receptor antibodies (TRAb) causing increased amounts of triiodothyronine (T3) and thyroxine (T4). This high level of thyroid hormones achieved by the negative feedback mechanism shuts off the secretion of thyrotropin or TSH.

Thyroiditis: An inflammation that damages thyroid follicles and can cause stored thyroid hormones to leak out, leading to increased thyroid hormone levels.

2.5.1.2 Hypothyroidism

It happens because thyroid hormones aren't being made or released normally, causing a slow metabolic rate. The main causes are:

Hashimoto's Thyroiditis: This is an autoimmune disorder characterized by the chronic inflammation and progressive destruction of thyroid tissue via T cell-mediated immunity plus antibody production (Caturegli et al., 2014).

Iodine Deficiency: The thyroid hormones require iodine. Iodine deficiency disrupts the synthesis of T3 and T4 resulting in spiking TSH and giving rise to goiter.

2.5.1.3 Thyroid Hormone Resistance

The mutations in the thyroid hormone receptor gene cause this rare condition. The body is unable to respond to thyroid hormones, even when the levels of hormones are normal or elevated (Pappa et al., 2021).

2.5.1.4 Goiter

Iodine deficiency, TSH stimulation from hypothyroidism, and the presence of thyroid-stimulating immunoglobulins are some potential reasons for goiters to occur (Caturegli et al., 2014; Somasundaram et al., 2020).

Fig. 1: Common causes of metabolic disorders in women (Retrieved from Microsoft Word 2016)

3 Impact of Metabolic Disorders on Female Reproductive Health

Metabolic disorders cause the following complications (Figure 2):

3.1 Menstrual Irregularities

PCOS, thyroid dysfunction, and other metabolic disorders cause hormonal imbalance and disruption of the HPO axis leading to prolonged cycles, menstruation, and heavy bleeding (Salem, 2021). For example, in PCOS, high insulin level increases androgen production, causing anovulation and irregular periods (Azziz et al., 2016). Both short-term health complications (anemia) and long-term fertility problems can occur.

3.2 Infertility and Ovulatory Dysfunction

PCOS, obesity, and thyroid disease can cause ovulatory dysfunction by impacting hormonal balances. Hyperandrogenic ovarian dysfunction results in hyperinsulinemia, associated with insulin resistance (Moran et al., 2011). Anovulation, a dominant cause of infertility, is induced by elevated androgens that disrupt follicle development (Melo et al., 2015). In addition, obesity complicates ovulation by creating chronic low-grade inflammation, which increases the leptin hormone that regulates reproductive function (Brewer & Balen, 2010). Ovulatory dysfunction is a major barrier to conception.

3.3 Pregnancy Complications (Gestational diabetes, Preeclampsia)

Pregnancy complications such as gestational diabetes, preeclampsia, and fetal growth abnormalities are found in women affected with metabolic disorders. People with pre-existing metabolic disorders (such as obesity or T2DM) are especially at risk for developing Gestational diabetes (American Diabetes Association, 2021). Gestational diabetes occurs due to high blood sugar levels during pregnancy. It occurs in women with obesity, insulin resistance, and metabolic syndrome. It can result in preterm birth and perinatal morbidity (American Diabetes Association, 2020).

Preeclampsia is a hypertensive disorder during pregnancy. It occurs in women with endothelial dysfunction, insulin resistance, and obesity. Women with preeclampsia are at increased risk of preterm delivery, low birth weight, and maternal cardiovascular diseases in later life (Ives et al., 2020). Some women could have gestational hypertension which has adverse impacts on maternal and fetal health, including stroke, kidney damage in mothers, and poor fetal growth (Brown et al., 2018).

3.4 Earlier Menopause

In addition to short-term effects, metabolic disorders cause problems such as early menopause. There is an association between a higher incidence of earlier menopause with obesity, resulting in menopausal complications e.g., hot flashes, night sweats, and mood disturbances (Ayers et al., 2010).

3.5 Gynecological Disorders

Complications such as endometrial hyperplasia, anovulatory bleeding, and an increased risk of endometrial cancer are also associated with metabolic disorders. These risks are increased by obesity-related chronic inflammation that stimulates estrogen production and reduces progesterone sensitivity (O'Rourke, 2014).



Fig. 2: Impact of metabolic disorders on female reproductive health (Retrieved from Microsoft Word 2016)

4 Diagnosis and Clinical Assessment

Diagnosis of the metabolic disorder includes clinical, biochemical, and imaging evaluation. It also looks at medical history, body mass index (BMI), and hyperandrogenism (symptoms of PCOS, metabolic syndrome, and diabetes). Hormonal profiles are done to check levels of LH, follicle-stimulating hormone (FSH), insulin, and testosterone. Glucose tolerance tests and lipid panels are used as metabolic status tests. It is possible with ultrasound to assess the morphology of the ovarian surface in PCOS. Early diagnosis and intervention can prevent complications, including infertility, menstrual irregularity, and long-term metabolic risks (Azziz et al., 2016; Lizneva et al., 2016).

5 Management Approaches

Interventions such as lifestyle modification, pharmacological treatment, and targeted therapies can help to control metabolic disorders.

5.1 Lifestyle Interventions

Important lifestyle interventions include changes in the pattern of nutrition and physical exercise. They are essential means of managing PCOS and metabolic syndrome. In order to regulate weight, improve insulin sensitivity, and adjust the hormonal balance, there should be an intake of a balanced diet that comprises whole grains, lean proteins, and unsaturated fats, along with regular exercise (Teede et al., 2019).

5.2 Pharmacological Interventions

Metformin is a commonly used drug to reduce insulin resistance, and androgen levels, and improve menstrual regularity and ovulatory function. In PCOS, drugs used to treat hyperandrogenism and irregular menstruation cycles include hormonal contraceptives. In patients with metabolic syndrome, cardiovascular risk factors can be managed with the use of antihypertensive medications and statins (Moran et al., 2011).

5.3 Behavioral Interventions

High levels of cortisol (stress hormone) for a longer duration can increase triglyceride and blood sugar. Therefore, managing stress through behavioral interventions like regular exercise, yoga, mindfulness, quality sleep, and breathing exercises is crucial to managing metabolic disorders. Regular exercise can help to enhance insulin sensitivity, lose weight, and promote cardiovascular health (Cleveland Clinic, 2023).

5.4 Assisted Reproductive Technologies

Ovulation induction and in-vitro fertilization are assisted reproductive technologies that can help to treat infertility. Treatment is best completed through a multidisciplinary approach using endocrinologists, gynecologists, dietitians, and mental health professionals. Early interventions can improve reproductive outcomes and prevent subsequent long-term complications of metabolic disorders (Azziz et al., 2016).

6 Prevention and Education

Nutrition with a balanced diet, regular physical exercise, healthy weight management, and diet control are needed to prevent metabolic disorders. In public health education, risks of obesity, insulin resistance, and a sedentary lifestyle should also be promoted. Screening tests should be done for early intervention and detection of PCOS and gestational diabetes. Education of women regarding the benefits of a healthy body mass index (BMI) is needed in combination with addressing modifiable risk factors that can prevent complications such as infertility and adverse pregnancy outcomes (Marchi et al., 2015; Escobar-Morreale, 2018). To prevent this, a combination of approaches is needed i.e. counseling along with health care access and community programs.

7 Future Research and Directions

Future research possibilities include enhanced early detection, individualized treatment approaches, and an understanding of how metabolic disorders impact female reproductive health. Specifically, new individualized therapies can be made by identifying genetic factors that cause metabolic disorders and infertility in women. Advanced studies should be promoted to find out the role of the gut microbiome, insulin resistance, and chronic inflammation in causing these disorders. Such longitudinal studies can then test the effects of early interventions on reproductive outcomes, and identify effective strategies to improve reproductive health and well-being. In addition, the combination of omics technologies (genomics and metabolomics) with artificial intelligence for predictive modeling will further improve prevention approaches. Improved policies that will help promote awareness and access to healthcare for women are still needed. There should also be long-term studies of how lifestyle modification, such as diet, exercise, and smoking, impacts fertility outcomes. This would lead to more efficient strategies for controlling metabolic disorders in women (Fauser et al., 2012a; Yong et al., 2021; Li et al., 2023).

8 Conclusion

PCOS, obesity, diabetes, and metabolic syndrome as well as thyroid dysfunction have a major impact on female reproductive health by impacting hormonal regulation, ovarian function, and the hypothalamic pituitary ovarian axis. Menstrual irregularities, infertility, problems of pregnancy, and gynecology are associated with these disorders. These problems can be solved by early diagnosis and individualized treatment. Comprehensive management strategies, lifestyle changes, medical therapeutics, and preventive education may reduce the impact. Nutrition with a balanced diet, regular physical exercise, healthy weight management, and diet control are important to prevent metabolic disorders. Future research on these underlying mechanisms should be focused on better understanding them, developing better diagnostic approaches, and designing targeted therapies to improve reproductive health outcomes in affected women.

References

Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., Peeters, R. P., & Sullivan, S. (2017). 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum. *Thyroid*, *27*(3), 315–389. https://doi.org/10.1089/thy.2016.0457

Ayers, B., Forshaw, M., & Hunter, M. S. (2010). The impact of attitudes towards the menopause on women's symptom experience: A systematic review. *Maturitas*, *65*(1), 28–36. https://doi.org/10.1016/j.maturitas.2009.10.016

Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016). Polycystic ovary syndrome. *Nature Reviews Disease Primers*, *2*(1). https://doi.org/10.1038/nrdp.2016.57

American Diabetes Association (2020). Standards of medical care in diabetes—2020. *Diabetes Care*, 43(Suppl. 1), S1–S212. https://doi.org/10.2337/dc20-Sint

American Diabetes Association (2021). Standards of medical care in diabetes—2021. *Diabetes Care*, 44(Supplement 1), S1-S232. https://doi.org/10.2337/dc21-S002

Aboeldalyl, S., James, C., Seyam, E., Ibrahim, E. M., Shawki, H. E., & Amer, S. (2021). The role of chronic inflammation in polycystic ovarian syndrome—A systematic review and meta-analysis. *International Journal of Molecular Sciences, 22*(5), 2734. https://doi.org/10.3390/ijms22052734

Balen, A. H., Morley, L. C., Misso, M., Franks, S., Legro, R. S., Wijeyaratne, C. N., Stener-Victorin, E., Fauser, B. C. J. M., Norman, R. J., & Teede, H. (2016a). The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. *Human Reproduction Update*, *22*(6), 687–708. https://doi.org/10.1093/humupd/dmw025

Balen, A. H., Morley, L. C., Misso, M., Franks, S., Legro, R. S., Wijeyaratne, C. N., Stener-Victorin, E., Fauser, B. C. J. M., Norman, R. J., & Teede, H. (2016b). The management of anovulatory infertility in women with polycystic ovary syndrome: An analysis of the evidence to support the development of global WHO guidance. *Human Reproduction Update*, *22*(6), 687–708. https://doi.org/10.1093/humupd/dmw025

Blüher, M. (2019). Obesity: global epidemiology and pathogenesis. *Nature Reviews Endocrinology*, *15*(5), 288–298. https://doi.org/10.1038/s41574-019-0176-8

Brewer, C. J., & Balen, A. H. (2010). The adverse effects of obesity on conception and implantation. *REPRODUCTION*, *140*(3), 347–364. https://doi.org/10.1530/rep-09-0568

Brickman, W., Catalano, P., Clayton, P. E., Deerochanawong, C., Hamilton, J., Lashley, P. M., Lawrence, J. M., Lebenthal, Y., Mccance, D. R., Tam, W. H., Kuang, A., Lowe, L. P., Metzger, B. E., Scholtens, D., & Lowe, W. (2018). Gestational Diabetes (GDM) and Childhood Disorders of Glucose Metabolism—Hyperglycemia and Adverse Pregnancy Outcome Follow-Up Study (HAPO FUS). *Diabetes*, *67*(Supplement_1). https://doi.org/10.2337/db18-116-or

Brown, M., Magee, L., Kenny, L., Ananth Karumanchi, S., Mccarthy, F., Saito, S., Hall, D. R., Warren, C., Adoyi, G., & Ishaku, S. (2018). 187. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. *Pregnancy Hypertension*, *13*, S6–S7. https://doi.org/10.1016/j.preghy.2018.08.022

Cassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016). Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies. *Human Reproduction*, *31*(11), 2619–2631. https://doi.org/10.1093/humrep/dew243

Catalano, P. M., & Shankar, K. (2017). Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. *BMJ (Clinical Research Ed.)*, *356*, j1–j1. https://doi.org/10.1136/bmj.j1

Caturegli, P., De Remigis, A., & Rose, N. R. (2014). Hashimoto thyroiditis: Clinical and diagnostic criteria. *Autoimmunity Reviews*, *13*(4–5), 391–397. https://doi.org/10.1016/j.autrev.2014.01.007

Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, T. 1 D. S. (2014). Type 1 diabetes through the life span: a position statement of the American Diabetes Association. *Diabetes Care*, *37*(7), 2034–2054. https://doi.org/10.2337/dc14-1140

Cleveland Clinic (2023). *Metabolic syndrome*. https://my.clevelandclinic.org/health/diseases/10783-metabolic-syndrome

Chang, K.-J., Chen, J.-H., & Chen, K.-H. (2024). The Pathophysiological Mechanism and Clinical Treatment of Polycystic Ovary Syndrome: A Molecular and Cellular Review of the Literature. *International Journal of Molecular Sciences, 25*(16), 9037. https://doi.org/10.3390/ijms25169037

DeFronzo, R. A. (2004). Pathogenesis of type 2 diabetes mellitus. *Medical Clinics of North America*, *88*(4), 787–835. https://doi.org/10.1016/j.mcna.2004.04.013

Duffey, K. J., Gordon-Larsen, P., Jacobs, D. R., Jr, Williams, O. D., & Popkin, B. M. (2007). Differential associations of fast food and restaurant food consumption with 3-y change in body mass index: the Coronary Artery Risk Development in Young Adults Study. *The American Journal of Clinical Nutrition, 85*(1), 201–208. https://doi.org/10.1093/ajcn/85.1.201

Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015). Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. *Endocrine Reviews*, *36*(5), 487–525. https://doi.org/10.1210/er.2015-1018

Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. *Nature Reviews Endocrinology*, *14*(5), 270–284. https://doi.org/10.1038/nrendo.2018.24

Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., Boivin, J., Petraglia, F., Wijeyeratne, C. N., Norman, R. J., Dunaif, A., Franks, S., Wild, R. A., Dumesic, D., & Barnhart, K. (2012a). Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. *Fertility and Sterility*, *97*(1), 28-38.e25. https://doi.org/10.1016/j.fertnstert.2011.09.024

Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., Boivin, J., Petraglia, F., Wijeyeratne, C. N., Norman, R. J., Dunaif, A., Franks, S., Wild, R. A., Dumesic, D., & Barnhart, K. (2012b). Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. *Fertility and Sterility*, *97*(1), 28-38.e25. https://doi.org/10.1016/j.fertnstert.2011.09.024

Flegal, K. M., Kruszon-Moran, D., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2016). Trends in Obesity among Adults in the United States, 2005 to 2014. *JAMA*, *315*(21), 2284–2291. https://doi.org/10.1001/jama.2016.6458

Göbl, C. S., Bozkurt, L., Prikoszovich, T., Winzer, C., Pacini, G., & Kautzky-Willer, A. (2011). Early Possible Risk Factors for Overt Diabetes after

Gestational Diabetes Mellitus. *Obstetrics & Gynecology*, *118*, 71–78. https://api.semanticscholar.org/CorpusID:24654085

Gregor, M. F., & Hotamisligil, G. S. (2011). Inflammatory Mechanisms in Obesity. *Annual Review of Immunology*, *29*(1), 415–445. https://doi.org/10.1146/annurev-immunol-031210-101322

Heindel, J. J., Newbold, R., & Schug, T. T. (2015). Endocrine disruptors and obesity. *Nature Reviews Endocrinology*, *11*(11), 653–661. https://doi.org/10.1038/nrendo.2015.163

Ives, C. W., Sinkey, R., Rajapreyar, I., Tita, A. T. N., & Oparil, S. (2020). Preeclampsia—Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. In *Journal of the American College of Cardiology* (Vol. 76, Issue 14, pp. 1690–1702). Elsevier Inc. https://doi.org/10.1016/j.jacc.2020.08.014

Kim, J., & Lee, J. (2021). Role of obesity-induced inflammation in the development of insulin resistance and type 2 diabetes: history of the research and remaining questions. *Annals of Pediatric Endocrinology & Metabolism*, *26*(1), 1–13. https://doi.org/10.6065/apem.2040188.094

Krassas, G. E., Poppe, K., & Glinoer, D. (2010). Thyroid Function and Human Reproductive Health. *Endocrine Reviews*, *31*(5), 702–755. https://doi.org/10.1210/er.2009-0041

Lazarus, J. H., Bestwick, J. P., Channon, S., Paradice, R., Maina, A., Rees, R., Chiusano, E., John, R., Guaraldo, V., George, L. M., Perona, M., Dall'Amico, D., Parkes, A. B., Joomun, M., & Wald, N. J. (2012). Antenatal thyroid screening and childhood cognitive function. *The New England Journal of Medicine*, *366*(6), 493–501. https://doi.org/10.1056/NEJMoa1106104

Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., Welt, C. K., & Society, E. (2013). Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *The Journal of Clinical Endocrinology and Metabolism*, *98*(12), 4565–4592. https://doi.org/10.1210/jc.2013-2350

Li, Q., Chen, S., Dong, X., Fu, S., Zhang, T., Zheng, W., Tian, Y., & Huang, D. (2023). The Progress of Research on Genetic Factors of Recurrent Pregnancy Loss. In *Genetics Research* (Vol. 2023). Hindawi Limited. https://doi.org/10.1155/2023/9164374

Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016). Criteria, prevalence, and phenotypes of polycystic ovary syndrome. *Fertility and Sterility*, *106*(1), 6–15. https://doi.org/10.1016/j.fertnstert.2016.05.003

Loos, R. J. F., & Yeo, G. S. H. (2022). The genetics of obesity: from discovery to biology. *Nature Reviews. Genetics*, *23*(2), 120–133. https://doi.org/10.1038/s41576-021-00414-z

Marchi, J., Berg, M., Dencker, A., Olander, E. K., & Begley, C. (2015). Risks associated with obesity in pregnancy, for the mother and baby: a systematic review of reviews. *Obesity Reviews*, *16*(8), 621–638. https://doi.org/10.1111/obr.12288

Melo, A. S., Ferriani, R. A., & Navarro, P. A. (2015). Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. *Clinics (Sao Paulo, Brazil)*, *70*(11), 765–769. https://doi.org/10.6061/clinics/2015(11)09

Moran, L. J., Hutchison, S. K., Norman, R. J., & Teede, H. J. (2011). Lifestyle changes in women with polycystic ovary syndrome. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.cd007506.pub2

Martins, M. C., Trujillo, J., Freitas-Vilela, A. A., Farias, D. R., Rosado, E. L., Struchiner, C. J., & Kac, G. (2018). Associations between obesity candidate gene polymorphisms (fat mass and obesity-associated (FTO), melanocortin-4 receptor (MC4R), leptin (LEP) and leptin receptor (LEPR)) and dietary intake in pregnant women. *British Journal of Nutrition*, *120*(4), 454–463. https://doi.org/10.1017/S0007114518001423

Nolan, C. J., & Prentki, M. (2019). Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. *Diabetes and Vascular Disease Research*, *16*(2), 118–127. https://doi.org/10.1177/1479164119827611

Ohiagu, F. O., Chikezie, P. C., & Chikezie, C. M. (2021). Pathophysiology of diabetes mellitus and its Complications: Metabolic events and control. *Biomedical Research and Therapy*, *8*(3), 4243–4257. https://doi.org/10.15419/BMRAT.V8I3.663

O'Rourke, R. W. (2014). Endometrial hyperplasia, endometrial cancer, and obesity: convergent mechanisms regulating energy homeostasis and cellular proliferation. *Surgery for Obesity and Related Diseases*, *10*(5), 926–928. https://doi.org/10.1016/j.soard.2014.03.022

Pasquali, R., Patton, L., & Gambineri, A. (2007). Obesity and infertility. *Current Opinion in Endocrinology, Diabetes & Obesity*, *14*(6), 482–487. https://doi.org/10.1097/med.0b013e3282f1d6cb

Poppe, K. (2003). Thyroid autoimmunity and hypothyroidism before and during pregnancy. *Human Reproduction Update*, *9*(2), 149–161. https://doi.org/10.1093/humupd/dmg012

Pappa, T., & Refetoff, S. (2021). Resistance to Thyroid Hormone Beta: A Focused Review. *Frontiers in Endocrinology*, *12*, 656551. https://doi.org/10.3389/fendo.2021.656551

Rosenfield, R. L. (2015). The Diagnosis of Polycystic Ovary Syndrome in Adolescents. *Pediatrics*, *136*(6), 1154–1165. https://doi.org/10.1542/peds.2015-1430

Rethink Obesity (2023). *Pathophysiology of obesity – all about the science to obesity* https://www.rethinkobesity.global/global/en/weight-and-health/pathophysiology-of-obesity.html

Salem, A. M. (2021). Variation of leptin during menstrual cycle and its relation to the hypothalamic–pituitary–gonadal (Hpg) axis: A systematic review. *International Journal of Women's Health*, *13*, 445–458. https://doi.org/10.2147/IJWH.S309299

Samuel, V. T., & Shulman, G. I. (2012). Mechanisms for insulin resistance: common threads and missing links. *Cell*, *148*(5), 852–871. https://doi.org/10.1016/j.cell.2012.02.017

Somasundaram, N., Sumanatilleke, M., Katulanda, P., Garusinghe, C., Abhayarathna, S., Pathmanathan, S., Gunathilake, S., Subhasinghe, C., Wijesinghe, A., Arambewela, M., Dilrukshi, S., Vithiya, U., Ranathunga, I., Dissanayake, H., de Silva, N., Yogendranathan, N., Jayasuriya, C., Wijetunga, W., & Gamage, K. (2020). Thyroid Disorders. *Sri Lanka Journal of Diabetes Endocrinology and Metabolism*, *10*, 41. https://doi.org/10.4038/sjdem.v10i1.7420

Sowers, J. R., Epstein, M., & Frohlich, E. D. (2001). *Diabetes, Hypertension, and Cardiovascular Disease An Update Hypertension in the Diabetic*

Patient. American Heart Association. http://www.hypertensionaha.org

Srinivasan, S., Chen, L., Todd, J., Divers, J., Gidding, S., Chernausek, S., Gubitosi-Klug, R. A., Kelsey, M. M., Shah, R., Black, M. H., Wagenknecht, L. E., Manning, A., Flannick, J., Imperatore, G., Mercader, J. M., Dabelea, D., Florez, J. C., & ProDiGY Consortium (2021). The First Genome-Wide Association Study for Type 2 Diabetes in Youth: The Progress in Diabetes Genetics in Youth (ProDiGY) Consortium. *Diabetes, 70*(4), 996–1005. https://doi.org/10.2337/db20-0443

Thaker V. V. (2017). GENETIC AND EPIGENETIC CAUSES OF OBESITY. *Adolescent Medicine: State of the Art Reviews, 28*(2), 379–405

Taylor, R., Al-Mrabeh, A., Zhyzhneuskaya, S., Peters, C., Barnes, A. C., Aribisala, B. S., Hollingsworth, K. G., Mathers, J. C., Sattar, N., & Lean, M. E. J. (2018). Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. *Cell Metabolism*, *28*(4), 667. https://doi.org/10.1016/j.cmet.2018.08.010

Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & Network, I. P. (2019). Erratum. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Human Reproduction (Oxford, England)*, *34*(2), 388. https://doi.org/10.1093/humrep/dey363

Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999). The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *The Journal of Clinical Investigation*, *104*(6), 787–794. https://doi.org/10.1172/JCI7231

World Health Organization (2021). *Obesity and overweight*. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

Yoo, S. (2018). Dynamic Energy Balance and Obesity Prevention. *Journal of Obesity & Metabolic Syndrome, 27*(4), 203–212. https://doi.org/10.7570/jomes.2018.27.4.203

Yong, J., Johnson, J. D., Arvan, P., Han, J., & Kaufman, R. J. (2021). Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus. *Nature Reviews. Endocrinology*, *17*(8), 455–467. https://doi.org/10.1038/s41574-021-00510-4

Zehravi, M., Maqbool, M., & Ara, I. (2021). Polycystic ovary syndrome and reproductive health of women: a curious association. *International Journal of Adolescent Medicine and Health*, *33*(6), 333–337. https://doi.org/10.1515/ijamh-2021-0031